Abstract
The frequencies of chromosomal aberrations and sister-chromatid exchanges (SCE) after exposure to β-lapachone, an activator of mammalian topoiomerase I, were studied in Chinese hamster cells. A dose-dependent increase in the frequencies of SCE was observed in continuous treatments with β-lapachone. Chromatid-type aberrations were obtained in cells exposed to β-lapachone for one cell cycle but also in cells exposed during the G2 phase of the cell cycle, with a marked induction of exchange-type aberrations for both treatment schedules. We therefore propose that activation of topoisomerase I by β-lapachone results in the production of chromosomal alterations. The cell cycle dependence of β-lapachone clastogenic effects strongly suggests a mechanism for the formation of chromosomal aberrations after this drug closely resembling the one observed for the topoisomerase I inhibitor, camptothecin.
| Original language | English |
|---|---|
| Pages (from-to) | 263-267 |
| Number of pages | 5 |
| Journal | Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis |
| Volume | 288 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1993 |
Fingerprint
Keywords
- Chromosomal aberrations
- Sister-chromatid exchanges
- Topoisomerase I
- β-Lapachone
ASJC Scopus subject areas
- Molecular Biology
- Health, Toxicology and Mutagenesis
Cite this
The production of chromosomal alterations by β-lapachone an activator of topoisomerase I. / Degrassi, Francesca; De Salvia, Rosella; Berghella, Libera.
In: Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, Vol. 288, No. 2, 1993, p. 263-267.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The production of chromosomal alterations by β-lapachone an activator of topoisomerase I
AU - Degrassi, Francesca
AU - De Salvia, Rosella
AU - Berghella, Libera
PY - 1993
Y1 - 1993
N2 - The frequencies of chromosomal aberrations and sister-chromatid exchanges (SCE) after exposure to β-lapachone, an activator of mammalian topoiomerase I, were studied in Chinese hamster cells. A dose-dependent increase in the frequencies of SCE was observed in continuous treatments with β-lapachone. Chromatid-type aberrations were obtained in cells exposed to β-lapachone for one cell cycle but also in cells exposed during the G2 phase of the cell cycle, with a marked induction of exchange-type aberrations for both treatment schedules. We therefore propose that activation of topoisomerase I by β-lapachone results in the production of chromosomal alterations. The cell cycle dependence of β-lapachone clastogenic effects strongly suggests a mechanism for the formation of chromosomal aberrations after this drug closely resembling the one observed for the topoisomerase I inhibitor, camptothecin.
AB - The frequencies of chromosomal aberrations and sister-chromatid exchanges (SCE) after exposure to β-lapachone, an activator of mammalian topoiomerase I, were studied in Chinese hamster cells. A dose-dependent increase in the frequencies of SCE was observed in continuous treatments with β-lapachone. Chromatid-type aberrations were obtained in cells exposed to β-lapachone for one cell cycle but also in cells exposed during the G2 phase of the cell cycle, with a marked induction of exchange-type aberrations for both treatment schedules. We therefore propose that activation of topoisomerase I by β-lapachone results in the production of chromosomal alterations. The cell cycle dependence of β-lapachone clastogenic effects strongly suggests a mechanism for the formation of chromosomal aberrations after this drug closely resembling the one observed for the topoisomerase I inhibitor, camptothecin.
KW - Chromosomal aberrations
KW - Sister-chromatid exchanges
KW - Topoisomerase I
KW - β-Lapachone
UR - http://www.scopus.com/inward/record.url?scp=0027218533&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027218533&partnerID=8YFLogxK
U2 - 10.1016/0027-5107(93)90093-U
DO - 10.1016/0027-5107(93)90093-U
M3 - Article
C2 - 7688086
AN - SCOPUS:0027218533
VL - 288
SP - 263
EP - 267
JO - Mutation Research
JF - Mutation Research
SN - 0027-5107
IS - 2
ER -